---
title: "A Study Assessing HMB-002 in Participants With Von Willebrand Disease"
description: "This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and effica"
url: "https://www.clareohealth.com/clinical-trials/NCT06754852"
---

This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study evaluating HMB-002 in participants with VWD. Part A of the study involves a single ascending dose (SAD) regimen design to establish safety, tolerability, PK, and PD effect. In Part B of the study, the safety and tolerability of repeat dosing will be established prior to cohort expansion to explore efficacy. Part C will evaluate the safety, PK, and PD of a single concomitant dose of HMB-002 and factor concentrate with Type 3 VWD or Type 1 VWD with low residual VWF and FVIII who use factor concentrate as prophylaxis.

## Key Facts

**ID:** NCT06754852
**Status:** RECRUITING
**Phase:** PHASE1/PHASE2
**Type:** INTERVENTIONAL
**Enrollment:** 108
**Sponsor:** Hemab ApS

## Conditions

- Von Willebrand Disease (VWD)
- Von Willebrand Disease (VWD), Type 1
- Von Willebrand Disease (VWD), Type 2
- Von Willebrand Disease (VWD), Type 3

## Interventions

**DRUG: HMB-002 (Part A)**
HMB-002 will be administered subcutaneously. Part A will utilize sentinel dosing. The planned duration of study participants in Part A is approximately 12 weeks.

**DRUG: HMB-002 (Part B)**
HMB-002 will be administered subcutaneously. Part B dosing intervals will be determined following evaluation of Part A results. The planned duration of study participants in Part B will be approximately 21 weeks.

**DRUG: HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)**
HMB-002 will be administered as a single dose with a concomitant single dose of factor concentrate. The planned duration of study participants in Part C will be approximately 17 weeks.

## Eligibility

Key Inclusion Criteria: 1. Weight 50 to 120 kg, inclusive. 2.

## Who Can Participate

**Minimum age:** 16

**Maximum age:** 69

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Emory Children's Center, Atlanta, Georgia, United States
- Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
- Tulane University School of Medicine, New Orleans, Louisiana, United States
- University of Michigan Hospitals, Department of Hemophilia and Coagulation Disorders, Ann Arbor, Michigan, United States
- Mayo Clinic - Rochester, Rochester, Minnesota, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States
- The University of Texas Southwestern Medical Center, Dallas, Texas, United States
- Washington Institute For Coagulation (WIC), Seattle, Washington, United States
- Fiona Stanley Hospital, Murdoch, Perth, Australia
- Royal Prince Alfred Hospital, Camperdown, Sydney, Australia
- The Alfred Hospital, Melbourne, Victoria, Australia
- Basingstoke and North Hampshire Hospital, Basingstoke, Hampshire, United Kingdom
- St George's Hospital, Tooting, London, United Kingdom
- Royal London Hospital, Whitechapel, London, United Kingdom
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
- University Hospital of Wales, Cardiff, United Kingdom
- St James's University Hospital, Leeds Haemophilia Centre, Leeds, United Kingdom
- Royal Liverpool and Broadgreen University Hospitals NHS TRUST, The Roald Dahl Haemostasis and Thrombosis Centre, Liverpool, United Kingdom
- Richmond Pharmacology, London, United Kingdom
- St Thomas' Hospital, London, United Kingdom

## Contact Information

**Clinical Trials**
Email: clinicaltrials@hemab.com
Phone: 080 8304 6409

## Important Dates

**Study start:** February 6, 2025

**Completion date:** July 1, 2027

**Last updated:** June 30, 2026

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06754852)
